• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于替加环素药代动力学/药效学目标的剂量优化。

Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline.

机构信息

Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Huaiyin District, Jinan 250021, China.

Medical Department, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwu Road, Huaiyin District, Jinan 250021, China.

出版信息

J Glob Antimicrob Resist. 2021 Jun;25:315-322. doi: 10.1016/j.jgar.2021.04.006. Epub 2021 May 4.

DOI:10.1016/j.jgar.2021.04.006
PMID:33957288
Abstract

Tigecycline, a new first-in-class glycylcycline antibiotic, has shown promising efficacy against a broad range of micro-organisms. It is widely prescribed for various infections, with most prescriptions being considered for off-label use. However, only a few years after its approval by the US Food and Drug Administration (FDA), tigecycline is suspected of increasing all-cause mortality. Some clinicians have suggested such unfavourable outcomes correlate with inadequate drug exposure at the infection site. The pharmacokinetic/pharmacodynamic (PK/PD) profile of a drug plays an important role in predicting its antibiotic effect, which for tigecycline is determined as the ratio of area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC). In this study, PK/PD targets based on infection sites, bacterial isolates and patient populations are discussed. Generally, a higher dosage of tigecycline for the treatment of serious infections has been recommended in previous reports. However, the latest finding of tigecycline's atypical protein binding property requires consideration when recommending further use. In addition, combination therapy with other antibiotics provides another option by potentially lowering the MICs of multidrug-resistant bacteria.

摘要

替加环素是一种新型的甘氨酰环素类抗生素,对广泛的微生物具有良好的疗效。它被广泛用于各种感染的治疗,大多数处方被认为是超适应证使用。然而,在替加环素获得美国食品和药物管理局(FDA)批准后的短短几年内,它就被怀疑会增加全因死亡率。一些临床医生认为,这种不良结局与感染部位药物暴露不足有关。药物的药代动力学/药效学(PK/PD)特征在预测其抗生素效果方面起着重要作用,替加环素的效果由浓度-时间曲线下面积(AUC)与最小抑菌浓度(MIC)的比值来确定。在本研究中,讨论了基于感染部位、细菌分离株和患者人群的 PK/PD 目标。一般来说,之前的报告建议对严重感染采用更高剂量的替加环素治疗。然而,替加环素的非典型蛋白结合特性的最新发现需要在进一步推荐使用时加以考虑。此外,联合使用其他抗生素可能通过降低多重耐药菌的 MIC 值提供另一种选择。

相似文献

1
Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline.基于替加环素药代动力学/药效学目标的剂量优化。
J Glob Antimicrob Resist. 2021 Jun;25:315-322. doi: 10.1016/j.jgar.2021.04.006. Epub 2021 May 4.
2
Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.替加环素——一种新型甘氨酰环素类抗菌药物的药代动力学/药效学概况。
Diagn Microbiol Infect Dis. 2005 Jul;52(3):165-71. doi: 10.1016/j.diagmicrobio.2005.05.006.
3
Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.评估浓度-时间曲线下面积与最低抑菌浓度(预估 AUIC)的比值,作为重症监护病房中多重耐药菌引起肺炎患者接受替加环素治疗结局的预测指标。
Int J Infect Dis. 2019 May;82:79-85. doi: 10.1016/j.ijid.2019.03.011. Epub 2019 Mar 13.
4
Once daily high dose tigecycline - pharmacokinetic/pharmacodynamic based dosing for optimal clinical effectiveness: dosing matters, revisited.每日一次高剂量替加环素——基于药代动力学/药效学的给药以实现最佳临床疗效:重新审视给药问题
Expert Rev Anti Infect Ther. 2017 Mar;15(3):257-267. doi: 10.1080/14787210.2017.1268529. Epub 2016 Dec 22.
5
Tigecycline: a glycylcycline antimicrobial agent.替加环素:一种甘氨酰环素类抗菌剂。
Clin Ther. 2006 Aug;28(8):1079-1106. doi: 10.1016/j.clinthera.2006.08.011.
6
A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding.需要重新审视替加环素的临床折点:非典型非线性血浆蛋白结合的影响。
Int J Antimicrob Agents. 2017 Apr;49(4):449-455. doi: 10.1016/j.ijantimicag.2016.12.008. Epub 2017 Feb 22.
7
Susceptibility of Klebsiella spp. to tigecycline and other selected antibiotics.肺炎克雷伯菌属对替加环素和其他选定抗生素的敏感性。
Med Sci Monit. 2010 Jun;16(6):BR193-6.
8
Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.替加环素单独及联合黏菌素对体外药效动力学模型中临床分离的多重耐药鲍曼不动杆菌的药效学研究。
Int J Antimicrob Agents. 2017 May;49(5):609-616. doi: 10.1016/j.ijantimicag.2017.01.007. Epub 2017 Mar 16.
9
A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii.一项评估替加环素治疗多重耐药鲍曼不动杆菌所致医院获得性肺炎的药效学模拟研究。
Pak J Pharm Sci. 2014 May;27(3):463-7.
10
Pharmacokinetic and pharmacodynamic evaluation of tigecycline.替加环素的药代动力学和药效学评价。
Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1459-70. doi: 10.1517/17425255.2011.623126. Epub 2011 Sep 30.

引用本文的文献

1
Incidence, characteristics and risk factors of tigecycline-induced hypoglycaemia: a retrospective study from the real world.替加环素所致低血糖症的发生率、特征及危险因素:一项来自真实世界的回顾性研究
JAC Antimicrob Resist. 2025 May 17;7(3):dlaf076. doi: 10.1093/jacamr/dlaf076. eCollection 2025 Jun.
2
Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD.依拉环素的群体药代动力学与肺部建模以及微生物学折点和药代动力学/药效学临界值的确定
Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0106524. doi: 10.1128/aac.01065-24. Epub 2025 Jan 29.
3
Evaluating Risk Factors for Clinical Failure Among Tigecycline-Treated Patients.
评估替加环素治疗患者临床治疗失败的风险因素。
Infect Drug Resist. 2024 Dec 4;17:5387-5393. doi: 10.2147/IDR.S496809. eCollection 2024.
4
Impact of Tigecycline on Coagulation in Severe Infections and Effect of Vitamin K1 Intervention: A Retrospective Single-Center Analysis.替加环素对严重感染凝血功能的影响及维生素 K1 干预效果的回顾性单中心分析。
Med Sci Monit. 2024 Nov 3;30:e944778. doi: 10.12659/MSM.944778.
5
Population Pharmacokinetics of Tigecycline for Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.替加环素在接受连续肾脏替代治疗的危重症患者中的群体药代动力学。
Drug Des Devel Ther. 2024 Oct 5;18:4459-4469. doi: 10.2147/DDDT.S473080. eCollection 2024.
6
Updated antimicrobial dosing recommendations for obese patients.肥胖患者抗菌药物剂量调整的最新推荐。
Antimicrob Agents Chemother. 2024 May 2;68(5):e0171923. doi: 10.1128/aac.01719-23. Epub 2024 Mar 25.
7
Co-Administration of High-Dose Nebulized Colistin for Bacteremic Ventilator-Associated Pneumonia: Impact on Outcomes.大剂量雾化多黏菌素联合治疗菌血症性呼吸机相关性肺炎:对预后的影响。
Antibiotics (Basel). 2024 Feb 8;13(2):169. doi: 10.3390/antibiotics13020169.
8
Population pharmacokinetics and individualized dosing of tigecycline for critically ill patients: a prospective study with intensive sampling.重症患者替加环素的群体药代动力学与个体化给药:一项密集采样的前瞻性研究
Front Pharmacol. 2024 Jan 29;15:1342947. doi: 10.3389/fphar.2024.1342947. eCollection 2024.
9
Microextraction of Tigecycline Using Deep Eutectic Solvents and Its Determination in Milk by LC-MS/MS Method.采用深共晶溶剂提取替加环素及其 LC-MS/MS 法测定牛奶中的残留量
J Agric Food Chem. 2023 Aug 2;71(30):11716-11725. doi: 10.1021/acs.jafc.3c03023. Epub 2023 Jul 24.
10
Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates.新型及重新利用的抗生素在新生儿中用于对抗革兰氏阴性菌的应用。
Antibiotics (Basel). 2023 Jun 19;12(6):1072. doi: 10.3390/antibiotics12061072.